Grant: Project Grant - PA: Epigenetics/epigenomics in human health or disease
Université de Montréal
$100,000.00
Investigating the metabolic determinants of triple-negative breast cancer progression through chromatin dependencies
EF 2019-20
Résumé
Breast cancer is the most common cancer affecting women in North America. One of the subtypes of breast cancers, the triple-negative breast cancer subtype, comprises a heterogeneous group of highly aggressive tumors for which chemotherapies remain the standard of care. However, resistance to chemotherapy represents a major barrier to remission for nearly 60% of triple-negative breast cancer patients. Identification of additional therapeutic avenues to target this type of cancer is therefore a priority. The goal of this project is to identify how molecular changes that occur in triple-negative breast cancer cells contribute to the survival and proliferation of cancer cells despite exposure to drugs. In particular, we will use triple-negative breast cancer models presenting different responses to therapy to investigate how the reprogramming of cell identity upon development of drug resistance regulates the way that cancer cells use nutrients and resources to generate energy and building blocks required to proliferate. The results generated from this project will allow a comprehensive identification of the biology contributing to the advent of therapeutic resistance and could lead to the development of improved therapeutic avenues for the treatment of poor prognosis and resistant breast cancers.
Programme
Project Grant - PA: Epigenetics/epigenomics in human health or disease
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
431824
Name
Deblois Genevieve
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Cancer Biology & Therapeutics 2
Projecttitle
Investigating the metabolic determinants of triple-negative breast cancer progression through chromatin dependencies
Programtype2
Operating Grants
Orgnameinp2
Université de Montréal
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant - PA: Epigenetics/epigenomics in human health or disease
Keyworddelim
Cancer Drug Resistance; Cancer Epigenetics; Cancer Metabolism; Epigenetic Reprogramming; Gene Expression; Metabolic Flexibility; Regulation Of Chromatin Modification
Abstract
Breast cancer is the most common cancer affecting women in North America. One of the subtypes of breast cancers, the triple-negative breast cancer subtype, comprises a heterogeneous group of highly aggressive tumors for which chemotherapies remain the standard of care. However, resistance to chemotherapy represents a major barrier to remission for nearly 60% of triple-negative breast cancer patients. Identification of additional therapeutic avenues to target this type of cancer is therefore a priority. The goal of this project is to identify how molecular changes that occur in triple-negative breast cancer cells contribute to the survival and proliferation of cancer cells despite exposure to drugs. In particular, we will use triple-negative breast cancer models presenting different responses to therapy to investigate how the reprogramming of cell identity upon development of drug resistance regulates the way that cancer cells use nutrients and resources to generate energy and building blocks required to proliferate. The results generated from this project will allow a comprehensive identification of the biology contributing to the advent of therapeutic resistance and could lead to the development of improved therapeutic avenues for the treatment of poor prognosis and resistant breast cancers.
Competitiondate
202003
Approvedterm2
1 yr 0 mth
Pinamesdelim
Deblois, Genevieve
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~